Hereditary hemochromatosis is a common autosomal recessive disorder of iron metabolism, which in its homozygous form occurs in Caucasian populations with a prevalence of 0.2-0.5% (1, 2 ) . Characteristic of the disease is the excessive accumulation of dietary iron and a progressive rise in iron stores. This may lead to serious clinical consequences, including cirrhosis, cardiac failure, diabetes, arthritis, and hepatocellular carcinoma. Treatment involves removal of the iron burden by regular venesection and leads to a normal life expectancy if implemented before the development of cirrhosis (3 ) . Thus, early detection and treatment are critically important. The recent identification of a hemochromatosis gene (HFE, initially termed HLA-H) by Feder et al. (4 ) allows early genetic diagnosis and greatly simplifies the screening of a family once affected individuals have been identified. The HFE gene protein product is structurally similar to MHC class I-type molecules and interacts with ␤ 2 -microglobulin and the transferrin receptor to limit iron absorption (5, 6 ) . Three disease-associated mutations have been detected in the HFE gene. Most individuals with hemochromatosis (80 -100%, depending on the population studied) are homozygous for the mutation C282Y. In addition, a small number of compound heterozygotes for C282Y and a second mutation, H63D, may develop clinical iron overload (7 ) . Recently, we demonstrated that a third mutation, S65C, is enriched in hereditary hemochromatosis patients who have a mild form of the disease and who have no mutations at C282 or H63 (8 ) . Although mutations in the HFE gene thus account for most cases of hereditary hemochromatosis, it is clinically important that a minority of hereditary iron overload syndromes are not associated with mutations in the HFE gene. Absence of such mutations thus should not be interpreted to mean that the patient in question does not have hereditary iron overload (1, 2 ) .
Several assays for the identification of the C282Y and H63D point mutations and one assay for the detection of the S65C mutation have been described, but they are labor-intensive and costly because post-PCR processing by restriction enzyme digestion and gel electrophoresis analysis is necessary (9 ) . The LightCycler (Roche Molecular Biochemicals) is a combined microliter volume thermal cycler and fluorometer suitable for fast real-time fluorescence PCR. In addition, it is designed for mutation detection by melting point analysis with fluorescent hybridization probes using the fluorescence energy transfer (FRET) principle (10 ) . A LightCycler procedure to detect the C282Y mutation by the use of by real-time fluorescence PCR has recently been developed (11 ) , obviating the need for re-opening of PCR reaction tubes and post-PCR processing for this mutation.
We set out to construct a LightCycler PCR protocol for the simultaneous detection of the H63D and S65C mutations of the HFE gene, based on the principle of mutation detection by melting point analysis with FRET hybridization probes. Because the mutation causing the S65C variant [A3 T at nucleotide (nt) 193] is located only six nucleotides away from the mutation underlying H63D (nucleotides A193T and C187G), we used a "sensor" probe covering both nucleotide positions/both sites. Specifically, the sensor probe was designed complementary to the 63D mutant and the S65 wild type, whereas the anchor probe was constructed to cover an adjacent invariant gene segment. Thus, the 63D mutant allele is expected to yield the highest melting temperature (T m ), the H63 wild type a lower T m , and the 65C mutant an even lower T m . LightCycler PCR mutation analysis was performed as follows: Blood was obtained in 5-mL EDTA Vacutainer Tubes. DNA was isolated by a standard rapid lysis technique using the Qiagen QIAamp Blood kit, and LightCycler PCR was performed with the following oligonucleotides: Thereafter, melting curve analysis of amplicons was performed, starting from 45°C and proceeding until 85°C at a linear rate of 0.2°C/s. In this assay, the H63D mutant allele is expected from theoretical calculations to yield a T m of 69°C, whereas the fluorescent probe is expected to dissociate from an H63 wild-type allele at a significantly lower temperature because of the single-nucleotide misClinical Chemistry 45, No. 12, 1999 match C3 G at nt 187 of HFE cDNA. Furthermore, an allele wild type at AA position 63 (H63) but mutated at AA position 65 (65C) would contain two nucleotide mismatches with the fluorescent probe complementary to 63D and would be expected to melt at an even lower temperature.
In a first series, DNA samples from 12 unselected patients referred to us for HFE gene analysis were tested with this LightCycler protocol. As the reference method, they were also typed for the presence of the H63D mutation by a commercially available kit based on PCR amplification followed by oligonucleotide hybridization (ONH) to microtiter well-immobilized oligonucleotides specific for either the wild type (H63) or the mutation (63D). In this assay, biotin residues are incorporated into amplicons during PCR, which later serve to reveal oligonucleotide-bound amplicons by a streptavidin-enzyme conjugate and colorimetric detection (Vienna Laboratory). The absorbances found after hybridization to both single probes are recorded, and an absorbance ratio between 0.5 and 2.0 is recommended by the manufacturer to identify heterozygous H63D carriers, whereas absorbance ratios Ͼ2 are indicative of a homozygous state, either H63H63 or 63D63D. DNA of one patient exhibiting a homozygous H63 wild type (patient P1) and from another patient exhibiting the heterozygous genotype H63,63D (patient P2) as established by the PCR-ONH assay were carried further as controls in all further determinations with both the PCR-ONH and the LightCycler PCR procedure ("WT control" and "HET control"). This was necessary because the internal genotype controls contained in the kit were too short for the primer combination chosen for the LightCycler PCR.
LightCycler PCR yielded a T m for the control mutant 63D allele of 69.4 Ϯ 0.26°C (mean Ϯ SD; n ϭ 8 for subsequent results) and a 6.2°C lower T m of 63.2 Ϯ 0.35°C for the control wild-type H63 allele. The CV for the T m of the mutant 63D allele was lower (0.37%) than that of the wild-type H63 allele (0.56%), in agreement with the theoretical expectation. The relatively large T m difference allowed for a clear distinction between the H63 and 63D alleles (Fig. 1) . The PCR-ONH assay also clearly distinguished the control mutant 63D allele and the control wild-type H63 allele, with an absorbance ratio of 0.87 Ϯ 0.05 for the HET control DNA and an absorbance ratio Ͼ4.2 for the WT control DNA. Notably, the calculated 95% confidence interval for the absorbance ratio actually obtained with HET control DNA, 0.77-0.98, was much narrower than the confidence interval suggested by the manufacturer, 0.5-2.0.
Of the other 10 consecutive patients analyzed, unambiguous and identical genotype assignment by both methods was observed in 9 samples (Table 1) . However, LightCycler melting curve analysis of the DNA of patient 11 consistently yielded one peak corresponding to an H63D allele (T m of 69.4°C) and a distinct second peak with a T m of 59.3-59.4°C, or 3.8 -3.9°C lower than the T m of the H63 wild-type allele (Fig. 1) and thus clearly not contained within the T m confidence interval for either H63 or 63D. Because the lower T m of the H63D probe-H63 product is caused by one mismatch (C3 G at nt 187 of HFE cDNA), we suspected that the lower T m observed in this patient was attributable to the presence of a second nucleotide mismatch in the stretch of the HFE gene spanned by the 63D-targeted fluorescent hybridization probes, i.e., the presence of a third known mutation in the HFE gene, A193T, which encodes the S65C amino acid exchange. Interestingly, the PCR-ONH assay also yielded a subtly abnormal result in this patient: the observed absorbance ratio was 0.54 and would lead to a diagnosis of heterozygosity for H63D if interpreted according to the manufacturer's instructions. If, however, the narrower confidence interval that we determined ourselves (0.77-0.98) was used, the abnormal binding of the patient's "wild-type" allele to the wild-type oligonucleotide was obvious and also pointed to a base exchange near, but distinct from, the C3 G mutation at nt 187 of HFE cDNA. Therefore, the LightCycler PCR product of this patient was sequenced on an ABI Prism model 310, using either the 3Ј PCR primer or the 5Ј PCR primer in a standard Perkin-Elmer protocol, which identified the A193T mutation in addition to the C3 G mutation at nt 187 (H63D) in this patient. The patient was a 59-year-old man with a medical history of hepatomegaly. Apart from the S65C mutation, he carried only a heterozygous H63D mutation but no mutation at C282. In a second series, DNA from another 15 patients we had typed earlier for the H63D and S65C mutations by PCR plus HinfI restriction fragment length polymorphism and sequencing (8 ) was subjected to LightCycler PCR. Of these 15 samples, 10 carried the S65C mutation either alone or in conjunction with the H63D mutation. In all 15 samples, the LightCycler PCR Red curve, results of a DNA sample heterozygous for the H63D mutation but wild type at AA position 65. Pink curve, results of a DNA sample heterozygous for the H63D mutation and heterozygous for S65C. Blue curve, result obtained without DNA.
procedure unambiguously yielded the correct genotype assignment (data not shown). The presence of a polymorphic site in intron 4 of HFE recently has been shown to prevent amplification of some C282 wild-type alleles if primers are chosen to cover this site, causing overestimation of the frequency of C282Y homozygotes (12 ) . Indeed, in the PCR reaction described here, the down primer is localized on a polymorphic T/C at nt ϩ4 in intron 2 of HFE (ϳ70% T and 30% C). However, the presence of a TT, TC, or CC genotype at this site did not influence the efficiency of the PCR reaction and did not affect correct H63D and S65C genotype assignment (data not shown).
Thus, we have established a LightCycler PCR assay for the simultaneous detection of the H63D and S65C mutations in the HFE gene. When one fluorescent probe is targeted specifically to the H63D mutation, the H63D and S65C mutations cause easily recognizable T m curve shifts in opposite directions from the wild-type situation. This principle may be applicable to other situations in which mutations within close proximity are to be detected (13, 14 ) . In contrast to other multiplex formats, the procedure presented here is based solely on differences in T m shifts and utilizes only one fluorescence readout channel, allowing additional multiplexing by incorporation of ad- ............................................................................................................................ .................................... The analysis of samples using hybridization probes and melting curve analysis is like a fingerprint for a specific polymorphism, but in addition, it also clearly shows the presence of neighboring polymorphisms, which are not detectable with common techniques such as restriction fragment length polymorphisms. The procedure yields results superior to any solid-phase-based format that uses either microtiter plates or the new chip technology, where difficulties have been reported because of reactions/results between "yes" and "no" (15 ) ; it also yields better results when compared with DNA sequencing, which will not always find heterozygosity. In cases where multiple different mutations may occur in the vicinity of a "target" mutation (14 ), we suggest confirming any mutation with the appropriate mutation-specific probe. The potent immunosuppressant agent sirolimus (rapamycin; Wyeth-Ayerst) is undergoing clinical trials in solidorgan transplantation (1, 2 ) . Evidence suggests that therapeutic drug monitoring of trough sirolimus concentrations may be beneficial for two fundamental reasons: (a) a strong correlation between the trough concentration and the area under the concentration-time curve has been shown; and (b) a strong correlation between the evidence of toxicity and trough concentrations substantially Ͼ15 g/L has been reported (3 ). To date, there have been only HPLC methods available to measure sirolimus in human whole blood. These include HPLC with mass spectrometric detection (4, 5 ) and HPLC with ultraviolet detection (6 -9 ) . As an alternative, a semiautomated method utilizing the IMx analyzer (Abbott Diagnostics) that incorporates microparticle enzyme immunoassay (MEIA) technology has been developed. There are two versions of the MEIA for sirolimus in whole blood, the prototype version (Mode 1A) and the recently manufactured premarket version (Mode 1C). Both of these assays are undergoing evaluation based on their analytical performance and clinical use.
This study compares the analytical performance of the prototype MEIA (Mode 1A) with HPLC-tandem mass spectrometry (HPLC-MS) within one center through evaluation of interference with endogenous and exogenous compounds, imprecision, recovery, and the quantification range. In addition, blood samples from renal transplant patients receiving sirolimus therapy are compared using both methods. Throughout this study, HPLC-MS was performed as per our reported method (4 ) and MEIA according to manufacturer's instructions. All patient specimens were stored at Ϫ75°C until analysis.
Investigation into potential interferences in HPLC-MS and MEIA in relation to endogenous compounds was determined based on 209 samples collected into EDTA tubes from 23 renal transplant recipients not receiving sirolimus therapy. In patient samples with no sirolimus detected by HPLC-MS (Ͻ0.2 g/L), MEIA recorded a mean sirolimus concentration of 0.2 g/L, where the measured concentrations were 0.0 -2.3 g/L. Potential interference from some exogenous compounds was investigated. Tacrolimus (60 g/L), cyclosporin A (1000 g/L), and mycophenolic acid (50 mg/L) were supplemented into calibrator A (drug-free whole blood supplied by the manufacturer). 
